Drug intelligence / Profile preview

AZD5851

Development stage: Phase 2
Lead developer: AstraZeneca
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies, Vaccines & Immunotherapeutics
Administration: Intravenous

Overview

AZD5851 is an autologous chimeric antigen receptor T-cell (CAR-T) therapy under development for the treatment of glypican-3 (GPC3) positive advanced or recurrent hepatocellular carcinoma. The therapy consists of a patient's own T lymphocytes genetically modified to express a CAR specific for GPC3, a protein overexpressed in hepatocellular carcinoma but largely absent from healthy tissues. AZD5851 also incorporates a dominant negative transforming growth factor beta receptor II (dnTGFβRII) as an armoring strategy to block TGFβ signaling and protect CAR-T cells from immunosuppressive effects within the tumor microenvironment. The drug is being developed by AstraZeneca and AbelZeta Pharma and is currently in Phase 2 clinical trials for hepatocellular carcinoma[2][3][4][5].

Other names: autologous dntgf-brii-armored anti-gpc3 car t cells azd5851

Targets

TGFBR2 (TGF-β receptor type 2)GPC3 (Glypican-3)

Beyond the preview

Go deeper on AZD5851.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AZD5851.

Explore the full profile